In a unanimous decision, the U.S. Supreme Court rejected an attempt by anti-abortion groups to restrict access to the abortion medication mifepristone, citing a lack of standing to sue as the plaintiffs did not demonstrate direct harm. Justice Brett Kavanaugh noted that the plaintiffs, who neither prescribe nor manufacture the drug, could not show any injury in fact. The ruling ensures continued access to mifepristone, which is used in over half of medication abortions in the U.S., and is praised by medical organizations for its safety and efficacy. However, the legal battle over mifepristone is expected to continue, with three Republican-led states—Missouri, Idaho, and Kansas—likely to pursue further legal challenges. This ruling marks the Court's first abortion-related decision since overturning Roe v. Wade in 2022. The decision has been described as a relief for abortion rights advocates, though the future of the medication remains uncertain due to ongoing litigation.